PIEZO2 deficiency is a recognizable arthrogryposis syndrome: A new case and literature review.
Arthrogryposis
/ diagnosis
Child
Electromyography
Facies
Female
Gene Expression
Genetic Association Studies
/ methods
Genetic Predisposition to Disease
Genotype
High-Throughput Nucleotide Sequencing
Humans
Ion Channels
/ deficiency
Mutation
Nonsense Mediated mRNA Decay
Phenotype
Sequence Analysis, DNA
Syndrome
PIEZO2 deficiency
areflexia
arthrogryposis
decreased senses
neurophysiological examination
next-generation sequencing (NGS)
Journal
American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
12
01
2019
revised:
03
03
2019
accepted:
07
03
2019
pubmed:
4
4
2019
medline:
11
6
2020
entrez:
4
4
2019
Statut:
ppublish
Résumé
PIEZO2 encodes a mechanically activated cation channel, which is abundantly expressed in dorsal root ganglion neuron and sensory endings of proprioceptors required for light touch sensation and proprioception in mice. Biallelic loss-of-function mutations in PIEZO2 (i.e., PIEZO2 deficiency) were recently found to cause an arthrogryposis syndrome. Sixteen patients from eight families have been reported to date. Herein we report a new case, including detailed clinical characteristics and courses as well as comprehensive neurological features. The patient was a 12-year-old girl presenting with congenital multiple contractures, progressive severe scoliosis, prenatal-onset growth impairment, motor developmental delay with hypotonia and myopathy-like muscle pathology, mild facial features, and normal intelligence. Her neurological features included areflexia, impaired proprioception, and decreased senses. Neurophysiological examination revealed decreased amplitude of sensory nerve action potentials, absent H reflex, and prolongation of central conduction times. Clinical exome sequencing revealed a novel homozygous frameshift mutation in PIEZO2 (NM_022068: c.4171_4174delGTCA: p.Val1391Lysfs*39) with no detectable mRNA expression of the gene. PIEZO2 deficiency represents a clinical entity involving characteristic neuromuscular abnormalities and physical features. Next generation sequencing-based comprehensive molecular screening and extensive neurophysiological examination could be valuable for diagnosis of the disorder.
Identifiants
pubmed: 30941898
doi: 10.1002/ajmg.a.61142
doi:
Substances chimiques
Ion Channels
0
PIEZO2 protein, human
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
948-957Subventions
Organisme : Japan Agency for Medical Research and Development
ID : Program for an Integrated Database of Clinical and
Pays : International
Organisme : Japan Agency for Medical Research and Development
ID : Practical Research Project for Rare/Intractable Di
Pays : International
Organisme : Japan Foundation for Pediatric Research
Pays : International
Organisme : Ministry of Health, Labour and Welfare
ID : Research on Intractable Diseases/073
Pays : International
Organisme : the Japan Medical Association
ID : Medical Research Encouragement Prize
Pays : International
Organisme : the Ministry of Education, Culture, Sports, Science and Technology of Japan
ID : Grant-in-Aid for Scientific Research (C)/25460405
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.